Thermo Fisher Scientific (NYSE:TMO) PT Lowered to $610.00 at Barclays

Thermo Fisher Scientific (NYSE:TMO - Free Report) had its target price decreased by Barclays from $620.00 to $610.00 in a research note published on Wednesday, Benzinga reports. Barclays currently has an equal weight rating on the medical research company's stock.

A number of other equities research analysts have also recently issued reports on the company. Raymond James raised their target price on Thermo Fisher Scientific from $650.00 to $660.00 and gave the company an "outperform" rating in a research note on Thursday, July 25th. Bank of America raised their price target on Thermo Fisher Scientific from $600.00 to $675.00 and gave the company a "buy" rating in a report on Monday, September 16th. Stephens began coverage on Thermo Fisher Scientific in a report on Tuesday, October 1st. They set an "overweight" rating and a $680.00 price target on the stock. JPMorgan Chase & Co. raised their price target on Thermo Fisher Scientific from $650.00 to $670.00 and gave the company an "overweight" rating in a report on Friday, September 20th. Finally, Bernstein Bank raised their price target on Thermo Fisher Scientific from $565.00 to $625.00 and gave the company a "market perform" rating in a report on Tuesday. Five analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $655.50.

Thermo Fisher Scientific Stock Performance

TMO stock traded down $9.89 during mid-day trading on Wednesday, reaching $576.49. The company had a trading volume of 2,046,662 shares, compared to its average volume of 1,467,838. The company has a quick ratio of 1.37, a current ratio of 1.72 and a debt-to-equity ratio of 0.64. The stock has a market capitalization of $220.06 billion, a P/E ratio of 36.98, a P/E/G ratio of 3.85 and a beta of 0.77. Thermo Fisher Scientific has a one year low of $415.60 and a one year high of $627.88. The stock's 50-day simple moving average is $607.04 and its two-hundred day simple moving average is $584.39.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its earnings results on Wednesday, July 24th. The medical research company reported $5.37 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $5.13 by $0.24. The company had revenue of $10.54 billion for the quarter, compared to analysts' expectations of $10.50 billion. Thermo Fisher Scientific had a return on equity of 18.22% and a net margin of 14.69%. The firm's quarterly revenue was down 1.4% compared to the same quarter last year. During the same period last year, the business posted $5.15 earnings per share. Research analysts anticipate that Thermo Fisher Scientific will post 21.72 EPS for the current year.

Insiders Place Their Bets

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 300 shares of the firm's stock in a transaction dated Friday, July 26th. The stock was sold at an average price of $600.85, for a total transaction of $180,255.00. Following the completion of the sale, the executive vice president now directly owns 17,887 shares in the company, valued at approximately $10,747,403.95. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 300 shares of the firm's stock in a transaction dated Friday, July 26th. The stock was sold at an average price of $600.85, for a total transaction of $180,255.00. Following the completion of the sale, the executive vice president now directly owns 17,887 shares in the company, valued at approximately $10,747,403.95. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Marc N. Casper sold 10,000 shares of the firm's stock in a transaction dated Wednesday, July 31st. The stock was sold at an average price of $617.21, for a total value of $6,172,100.00. Following the sale, the chief executive officer now owns 123,816 shares of the company's stock, valued at $76,420,473.36. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 23,084 shares of company stock worth $14,094,292. 0.34% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Thermo Fisher Scientific

Institutional investors have recently made changes to their positions in the company. Signature Resources Capital Management LLC lifted its holdings in shares of Thermo Fisher Scientific by 318.2% during the 2nd quarter. Signature Resources Capital Management LLC now owns 46 shares of the medical research company's stock valued at $25,000 after buying an additional 35 shares during the last quarter. New Millennium Group LLC acquired a new stake in shares of Thermo Fisher Scientific during the 2nd quarter valued at about $29,000. Stephens Consulting LLC raised its stake in shares of Thermo Fisher Scientific by 116.0% in the 2nd quarter. Stephens Consulting LLC now owns 54 shares of the medical research company's stock valued at $30,000 after acquiring an additional 29 shares in the last quarter. Headlands Technologies LLC bought a new position in shares of Thermo Fisher Scientific in the 1st quarter valued at approximately $32,000. Finally, Bank & Trust Co bought a new position in shares of Thermo Fisher Scientific in the 2nd quarter valued at approximately $33,000. 89.23% of the stock is currently owned by institutional investors and hedge funds.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.